Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series
Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series
批准号:
9048725
负责人:
Daniel C Pevear
金额:
$113.91万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-05 至 2019-06-30
关键词:
AddressAedesAlphavirusAmericasAmes AssayAntiviral AgentsArbovirusesBinding ProteinsBioavailableBiologicalBiological AvailabilityBlood CirculationCanis familiarisCaribbean regionCategoriesCell Culture TechniquesCell LineCenters for Disease Control and Prevention (U.S.)Central AmericaChemicalsChikungunya virusClinicalCulicidaeDNA VirusesDevelopmentDoseDrug EvaluationDrug KineticsEpidemicEuropeExposure toFeverFloridaGoalsHumanIn VitroIndividualInfectionLeadLibrariesLiver MicrosomesModelingMolecular TargetMusMusculoskeletal PainMutagenicity TestsNational Institute of Allergy and Infectious DiseaseOralPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsPharmacologyPhasePolyarthralgiasPopulationPositioning AttributePreventionPropertyProtein IsoformsRNARattusReportingRiskSafetySeriesSerum ProteinsSignal TransductionSmall Business Innovation Research GrantSolubilitySouth AmericaStagingStructure-Activity RelationshipTimeToxic effectToxicologyVaccinesVirusVirus DiseasesVirus InhibitorsVirus Replicationacute toxicitycandidate selectioncytotoxicexperiencegenotoxicityimprovedin vivoinhibitor/antagonistlead seriesmeetingsnovelnovel therapeuticspathogenpublic health relevancesafety studyscale upscreeningtransmission processvector mosquito
中文摘要
描述(由申请人提供):迫切需要用于治疗基孔肯雅病毒(CHIKV)感染的新型疗法,以解决该病原体在美洲的惊人传播。我们已经鉴定了一系列有效的、选择性的和口服生物可利用的CHIKV复制抑制剂。在此直接阶段 项目,我们将优化这一系列
CHIKV抑制剂进入预开发阶段,并将有史以来第一个CHIKV抗病毒候选药物推进IND使能研究。为了完成这项任务,我们将执行一项综合的药物化学优化/生物学特征分析活动,以优化该系列的效价、药物样特性和口服暴露。将确定一个或多个开发前候选药物,并通过候选药物选择研究推进到大鼠和犬的非GLP重复给药毒性中。
英文摘要
DESCRIPTION (provided by applicant): Novel therapies for the treatment of Chikungunya virus (CHIKV) infections are urgently needed to address the alarming spread of this pathogen across the Americas. We have identified a series of potent, selective, and orally bioavailable inhibitors of CHIKV replication. In this Direct to Phase project, we will optimize this series of
CHIKV inhibitors to Pre-Development stage and advance a first ever CHIKV antiviral candidate to IND-enabling studies. To accomplish this task, we will execute an integrated medicinal chemistry optimization/biological profiling campaign to optimize the potency, drug-like properties and oral exposure of the series. One or more Pre-Development Candidates will be identified and advanced through candidate selection studies into non-GLP repeat-dose tox in both rats and dogs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery and Advancement of Chikungunya virus inhibitors
-
批准号:8905316
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2015
-
负责人:Daniel C Pevear
-
依托单位:
Advancement of antiviral inhibitors of chikungunya virus
-
批准号:10132230
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2015
-
负责人:Daniel C Pevear
-
依托单位:
CCR5 inhibitors that block HIV but not chemokines
-
批准号:6887677
-
项目类别:
-
资助金额:$31.36万
-
财政年份:2004
-
负责人:Daniel C Pevear
-
依托单位:
Development of Small-Molecule HIV Entry Inhibitors
-
批准号:6792155
-
项目类别:
-
资助金额:$87.43万
-
财政年份:2001
-
负责人:Daniel C Pevear
-
依托单位:
海外基金